Explore News By Topic

05/20/2020

Lynparza approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The approval by the US Food and Drug Administration... Read More

05/15/2020

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy

Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in months... Read More

12/16/2019

FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More

07/13/2018

FDA Approves Enzalutamide (Xtandi) for Non-Metastatic Castration-Resistant Prostate Cancer

July 13, 2018 – Today the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  Non-metastatic CRPC is a clinical state in which PSA levels begin to rise in patients being treated with androgen deprivation therapy (ADT), but metastases are... Read More

06/04/2018

Prostate Cancer Foundation’s Statement on Late-Breaking ASCO Presentation Regarding Racial Differences in Prostate Cancer and Call for Greater Diversity in Clinical Trial Participation

JUNE 1, 2018  - Each year three million men in the U.S. battle prostate cancer and on average one in nine men will be diagnosed in their lifetime. However, there are significant racial disparities about the impact of the disease, particularly for men of African descent. Compared to men of... Read More

05/09/2018

Prostate Cancer Foundation Statement on U.S. Preventive Services Task Force Updated Prostate Screening Guidelines

Yesterday, the USPSTF updated its 2012 position on prostate cancer screening recommending that clinicians should selectively offer or provide periodic prostate-specific antigen (PSA)–based screening for prostate cancer for men between the ages of 55 to 69 (C recommendation). The USPSTF maintained its recommendation against PSA-based screening for prostate cancer in... Read More

05/08/2018

Clinical trial finds strong promise for new treatment that targets radiation directly to prostate cancer

May 8, 2018  A study published today in Lancet Oncology reported highly promising results from a phase 2 clinical trial testing a new treatment, 177Lu-PSMA-617, which targets radiation directly to prostate cancer. “We show in a prospective study that in men with metastatic castration-resistant prostate cancer who have progressed after standard... Read More

02/27/2018

New NCCN Guidelines Incorporate PCF-Funded Research on Cancer Risk Genes

Thanks in large part to the kinds of genetic and precision medicine that the Prostate Cancer Foundation has been funding, the National Comprehensive Cancer Network (NCCN) has issued updated prostate cancer guidelines that include new information about the role of family history and genomic testing to select precision medicine treatments... Read More

02/14/2018

FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer

February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC).  This clinical setting is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More

02/09/2018

Two new treatments have been found for prostate cancer patients who previously had no effective treatment options

Over the course of prostate cancer progression, there can come a time during which the cancer is progressing, but there are no treatments known to improve survival.  One of these “empty spaces” is when men who are being treated with androgen deprivation therapy (ADT) see their PSA levels begin to... Read More